Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Spremljeno u:
Glavni autori: | , , , , , , , , , , , , , |
---|---|
Format: | Članak |
Jezik: | engleski |
Izdano: |
Philipps-Universität Marburg
2023
|
Teme: | |
Online pristup: | PDF cijeli tekst |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
PDF cijeli tekstSignatura: |
urn:nbn:de:hebis:04-es2024-04361 |
---|---|
Datum izdanja: |
2024-01-17 |
Izvor: |
Erstveröffentlichung: Horvath, D., Temperton, N., Mayora-Neto, M. et al. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice. Sci Rep 13, 4648 (2023). https://doi.org/10.1038/s41598-023-31198-3 |
Downloads: |
9 (2024) |
Lizenz: |
https://creativecommons.org/licenses/by/4.0 |
URL pristupa: |
https://archiv.ub.uni-marburg.de/es/2024/0436 https://doi.org/10.1038/s41598-023-31198-3 |